ITALFARMACO S.P.A.

National and international clinical research networks (CRNs) are crucial to developing and delivering new therapies for rare disease patients. To better understand how to optimize the impact of CRNs for patient groups worldwide, the International Rare Diseases Research Consortium International Rare Diseases Research Consortium (IRDiRC) and the European Joint Programme on Rare Diseases (EJP RD) discussed opportunities and key considerations for CRNs in 2022. Their conclusions are now published in an article in Frontiers in Medicine, which is co-authored by our team member Samantha Parker. The publication “Fostering the international interoperability of clinical research networks to tackle undiagnosed and under-researched rare diseases” finds that CRNs can serve as a cornerstone for patient groups by enabling them to connect with clinicians around the world. To help deliver a more resilient global research system, a greater global linkage between national CRNs is crucial. Ways to overcome current hurdles include standardized data collection and sharing, as well as connecting expert knowledge and patient input, the paper concludes. At Italfarmaco, we are committed to addressing the unmet needs of the rare disease community and are thus engaged in fostering clinical research networks to ultimately provide solutions that have a real impact on the lives of patients and their families. #RareDiseases #PatientAdvocacy #IRDiRC #CRN #Duchenne #ERN Access the publication at this link: https://lnkd.in/dDdz4a4x  

We're #hiring a new Informatore scientifico del farmaco isf in Reggio nell'Emilia, Emilia-Romagna. Apply today or share this post with your network.

We're #hiring a new Informatore del farmaco in Naples, Campania. Apply today or share this post with your network.

Italfarmaco is proud to sponsor an ISPOR Educational Webinar on December 4th 2024, titled: “Leveraging the Value of Clinical Outcomes in DMD for Decision Making”. The webinar will be moderated by Dr. Francois Meyer and will include talks from three highly distinguished experts in DMD: Prof. Valeria Sansone; Conny Pelicaen and Dr. Paolo Bettica. Don’t miss the opportunity to gain insights into DMD, from understanding disease progression to navigating key disease milestones, as well as the complexities of clinical trial design in this therapeutic area. Discover the importance of collaboration among patient advocates, clinicians, and industry to improve patient access to innovative treatments. Italfarmaco’s rare diseases mission is to bring new opportunities to the rare diseases community, with innovation, quality, knowledge and motivation that can help more people su­ffering from rare diseases, than ever before. For additional information: https://lnkd.in/epmWhwBm

We're #hiring a new Informatore medico scientifico in Greater Rome Metropolitan Area. Apply today or share this post with your network.

We're #hiring a new Isf Specialist in Milan, Lombardy. Apply today or share this post with your network.

We're #hiring a new ISF in Salerno, Campania. Apply today or share this post with your network.

We're #hiring a new Informatore scientifico del farmaco in Cremona, Lombardy. Apply today or share this post with your network.

Auguri alla Fondazione Policlinico Universitario Agostino Gemelli IRCCS per i suoi 60 anni di attività in cui ha portato avanti un impegno instancabile verso pazienti e famiglie, offrendo cure di eccellenza, innovazione e alta specializzazione. Un luogo dove dedizione e progresso scientifico si incontrano, formando i professionisti della sanità di domani e migliorando costantemente la qualità della vita di chi si affida alle loro cure. Un ringraziamento speciale va ai 500 ricercatori e alle migliaia di medici, infermieri e operatori sanitari che ogni giorno si dedicano a formazione, ricerca e assistenza, con particolare attenzione a settori fondamentali come oncologia, malattie dell’invecchiamento e neurodegenerative, malattie neuromuscolari infantili, cardiologia e gastroenterologia. Non tutte le malattie hanno ancora una cura, ma la ricerca tiene viva la speranza. Per questo siamo orgogliosi di aver sostenuto la Charity Dinner della Fondazione Policlinico Universitario Agostino Gemelli IRCCS, un evento a supporto della ricerca sulla biopsia liquida, per offrire terapie personalizzate e sempre più efficaci. #policlinicogemelliroma #policlinogemelliIRCCS #italfarmaco

This year we are advisor and speaker at the World Orphan Drug Congress, one of the important gatherings for anyone involved in rare diseases. Bringing together over 130 experts from around the world, the congress will cover the entirety of the orphan drug space, from regulation and policy to global pricing and gene therapy. At the congress, two of our team members will also deliver key presentations: Samantha Parker, our Patient Advocacy and Communication Lead Rare Diseases, will moderate the panel discussion on “How does access differ across Europe” and lead a presentation titled “Patients voice in clinical trials design and outcomes”. Samantha will bring invaluable insights into the significance of capturing patients’ experiences with their disease, highlighting the importance of patient perspectives in shaping clinical research and outcomes. Ross Selby, our Value, Access & External Affairs Director for UK and Ireland will delve into the complexities of defining value in rare diseases with his presentation, “Challenges for defining value in Rare Diseases: the case for Duchenne muscular dystrophy (DMD)”. Join Samantha and Ross at the congress to gain firsthand insights into the latest developments in rare diseases and orphan drugs. Engage with them and other industry leaders as we discuss, share, and collaborate on solutions that will shape the future of rare disease treatments. Discover more about what’s on the agenda and how you can be part of this groundbreaking event here: https://lnkd.in/dkxcGrX